1. Home
  2. MRAM vs SABS Comparison

MRAM vs SABS Comparison

Compare MRAM & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Everspin Technologies Inc.

MRAM

Everspin Technologies Inc.

HOLD

Current Price

$14.61

Market Cap

353.8M

Sector

Technology

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.40

Market Cap

344.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRAM
SABS
Founded
2008
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
353.8M
344.8M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
MRAM
SABS
Price
$14.61
$3.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$18.50
$10.75
AVG Volume (30 Days)
956.1K
274.3K
Earning Date
04-29-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
78.53
EPS
N/A
N/A
Revenue
$49,417,000.00
N/A
Revenue This Year
$10.22
N/A
Revenue Next Year
$7.38
N/A
P/E Ratio
N/A
N/A
Revenue Growth
37.51
N/A
52 Week Low
$7.35
$1.85
52 Week High
$51.50
$5.15

Technical Indicators

Market Signals
Indicator
MRAM
SABS
Relative Strength Index (RSI) 39.22 38.47
Support Level $13.17 $3.38
Resistance Level $15.93 $4.02
Average True Range (ATR) 0.91 0.13
MACD -0.11 -0.04
Stochastic Oscillator 1.66 13.11

Price Performance

Historical Comparison
MRAM
SABS

About MRAM Everspin Technologies Inc.

Everspin Technologies Inc is a manufacturer of Magnetoresistive Random Access Memory (MRAM) technology. The company manufactures MRAM products using both captive and third-party manufacturing capabilities. It purchases industry-standard complementary metal-oxide semiconductor (CMOS) wafers from semiconductor foundries and perform back end of line (BEOL) processing that includes magnetic-bit technology at leased 200mm fabrication facility in Chandler, Arizona. It also manufactures full-flow 300mm CMOS wafers with STT-MRAM magnetic-bit technology integrated in BEOL. The company's customers are in key markets, such as industrial, medical, automotive/transportation, aerospace, and data center.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Share on Social Networks: